GLP-1 program infrastructure: the medication is no longer the hard part

There is a common misconception in GLP-1 strategy right now that the hard part is behind us. Access is easier, costs are controlled and now we can move on. Yes, access has gotten easier. Emerging indications beyond diabetes and obesity are expanding who qualifies for these medications, and demand keeps increasing. But easier access has created an entirely different problem. As GLP-1 access becomes commoditized, the medication itself stops being the differentiator. What happens after a patient gets their prescription written is where many programs start to fail.

Access without oversight is a real financial and clinical risk.

The cost pressure on plan sponsors has fueled a wave of direct-to-consumer platforms promising the same medication, faster and cheaper. A JAMA review of telehealth GLP-1 prescribing found that of the platforms studied that issued a prescription, a third did so based on an asynchronous questionnaire alone, with no live clinical interaction at any point in the process.

This gap shows up in the data. America’s Poison Centers has reported a 1,500% increase in calls related to GLP-1 accidental overdose or adverse effects since 2019, driven in part by dosing confusion, particularly with non-FDA-approved compounded formulations. A questionnaire can capture a lot of information, but it cannot catch a patient who will misread a dosing instruction, or one whose comorbidities should have changed their titration plan.

In my years of practice, I have seen the difference a live conversation makes. A patient who reports mild nausea on a form may describe something different when asked directly, and that distinction can change whether we hold a dose, slow a titration or move forward. Titration itself is not typically a fixed schedule. It is adjusted based on tolerance, weight trajectory and comorbidities. These adjustments require understanding of the patient in front of you, not just a protocol running automatically.

GLP-1 discontinuation rate is the clearest warning sign a program is not working. 

When a patient stops a GLP-1 within a few months, it is rarely because the medication failed. More often, it is because no one caught or treated side effects early enough, or the patient never got the behavioral support that makes the medication effects last. Lifestyle and behavior change support is not a nice-to-have along with the medication; it is what makes the effects of the medication durable over time.

The cost of getting this wrong is not just the money spent on the medication; it is at the cost of the patient’s health. Obesity and metabolic disease can be frustrating to treat, and the shame many patients carry around obesity treatment has improved but has not disappeared. A patient who cycles through another failed attempt often loses hope alongside time and money.

Fragmented access creates a patient safety problem.

Healthcare has become more specialized, which means more providers touch a single patient’s care. This increases overall risk of disjointed care, even with better data sharing and connected records. GLP-1s add a layer to that problem. With some DTC options, a patient’s other providers have limited visibility into what they have been prescribed, and compounded medications from DTC channels often do not feed into Surescripts data that help inform providers. Without that visibility, fragmentation stops being an inconvenience and becomes a safety risk, because a provider managing a patient’s other conditions may not know the full scope of medications impacting the picture if the patient does not disclose it themselves.

That risk will only grow. Research is now exploring GLP-1s for conditions well beyond diabetes and obesity, including Parkinson’s disease, Alzheimer’s disease and substance use disorder. As the reasons a patient may be on a GLP-1 multiply, so does the need for every provider on that patient’s care team to know it is on the medication list. A program built only for fast access cannot scale with that complexity. It becomes one more disconnected piece of a patient’s care at a time when coordination is important.

Where this leaves plan sponsors.

The GLP-1 landscape is not going to slow down. New indications, new formulations and new outcomes data will keep arriving over the coming years, and each will ask plan sponsors to revisit decisions they thought were settled. The organizations that navigate that well will not be the ones with the most restrictive access policies. They will be the ones with enough clinical flexibility to adapt as the evidence evolves.

Long-term value depends on patients having real clinical support behind the medication, not just access to it. That is the model we have built at Teladoc Health. Clinicians with obesity care experience guide titration, monitor for side effects early and stay connected to the rest of a patient’s care, pairing flexible coverage options that keep FDA-approved medications affordable without cutting out the clinical support that helps them work.

The medication will only get a patient so far. Whether the patient actually experiences the outcome the medication promises depends on what is built around it.